Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: David S. who wrote (3165)	12/5/1997 7:23:00 PM
From: Zirdu	Read Replies (1) \| Respond to of 6136

David S. Why do you believe Viracept will be around for decades? I would appreciate hearing your reasoning. If, by chance, this is another of your sarcastic comments, and you really mean that Viracept will NOT be around for decades, I would appreciate hearing you state this directly, and give your reasons for this opinion. Thanks. RR

To: David S. who wrote (3165)	12/5/1997 10:37:00 PM
From: JOHN W.	Respond to of 6136

Send some cans of dog food too. I love the reemergence of the "old" David S. in addition to all the new bear posters that have appeared, it is a very positive sign. Fantastic reasoning! Viracept will be obsolete in the fast changing therapy of HIV, However, the PI from VRTX and Glaxo (they only have one for the lying shorts and analyst) that could be on the mkt in 12-18 months poses a considerable threat and another one to be on the mkt in 2-3 yrs poses another threat in competition. If these drugs are near obsolete why are other companies continuing to pour money into their development that are still years away from being profitable? With the future of PIs being question, why not put the double whammy on AGPH after THYMITAQ news, these shorts need to go after VRTX.